SPTX: Held by 2 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics, Inc.

SPTX

Held by 2 specialist biotech funds

High short interest · No specialist buying

2 funds opened new positions. Short interest: 5.9% of float.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Signal Score

3.0/10

2 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 2 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

RA Capital ManagementNew

Perceptive AdvisorsNew

Short Interest

High short interestSI rising 2 periods (+52.1%)

Short Shares

3.01M

Change

+52.1%

Days to Cover

27.1

% of Float

5.9%

Settlement

Aug 14, 2026

Short interest over 3 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

RA Capital ManagementNEW POSITIONAug 14, 2026

Start free trialfor share counts, dollar values & AI analysis

1 more position change — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

ACRV2 funds APGE2 funds ARVN2 funds SPRY2 funds AXSM2 funds ASND2 funds ATXS2 funds ACLX2 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer